{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:05:43Z","timestamp":1780398343432,"version":"3.54.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1038\/ncprheum0572","type":"journal-article","created":{"date-parts":[[2007,8,30]],"date-time":"2007-08-30T13:30:12Z","timestamp":1188480612000},"page":"512-520","source":"Crossref","is-referenced-by-count":37,"title":["Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases"],"prefix":"10.1038","volume":"3","author":[{"given":"Eric","family":"Dayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Roux-Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0572_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/ajcp\/107.5.582","volume":"107","author":"JD Seebach","year":"1997","unstructured":"Seebach JD et al. (1997) The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol 107: 582\u2013591","journal-title":"Am J Clin Pathol"},{"key":"BFncprheum0572_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1172\/JCI1368","volume":"101","author":"Z Xing","year":"1998","unstructured":"Xing Z et al. (1998) IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101: 311\u2013320","journal-title":"J Clin Invest"},{"key":"BFncprheum0572_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1096\/fj.99-1003rev","volume":"15","author":"SA Jones","year":"2001","unstructured":"Jones SA et al. (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15: 43\u201358","journal-title":"FASEB J"},{"key":"BFncprheum0572_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clim.2005.08.004","volume":"117","author":"L Marnell","year":"2005","unstructured":"Marnell L et al. (2005) C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117: 104\u2013111","journal-title":"Clin Immunol"},{"key":"BFncprheum0572_CR5","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1084\/jem.190.12.1733","volume":"190","author":"M Griselli","year":"1999","unstructured":"Griselli M et al. (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190: 1733\u20131740","journal-title":"J Exp Med"},{"key":"BFncprheum0572_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1084\/jem.192.9.1353","volume":"192","author":"D Gershov","year":"2000","unstructured":"Gershov D et al. (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192: 1353\u20131364","journal-title":"J Exp Med"},{"key":"BFncprheum0572_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/hmg\/ddh021","volume":"13","author":"AI Russell","year":"2004","unstructured":"Russell AI et al. (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13: 137\u2013147","journal-title":"Hum Mol Genet"},{"key":"BFncprheum0572_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.60.10.988","volume":"60","author":"KC Shin","year":"2001","unstructured":"Shin KC et al. (2001) Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 60: 988\u2013989","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0572_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499\u2013511","journal-title":"Circulation"},{"key":"BFncprheum0572_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557\u20131565","journal-title":"N Engl J Med"},{"key":"BFncprheum0572_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-145-1-200607040-00128","volume":"145","author":"NK Cook","year":"2006","unstructured":"Cook NK et al. (2006) The effect of including C-reactive protein in cardiovascular risk prediction model for women. Ann Intern Med 145: 21\u201329","journal-title":"Ann Intern Med"},{"key":"BFncprheum0572_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/archinte.166.13.1368","volume":"166","author":"AR Folsom","year":"2006","unstructured":"Folsom AR et al. (2006) An assessment of the incremental coronary risk prediction using C-reactive protein and other novel risk markers. The atherosclerosis risk in community study. Ann Intern Med 166: 1368\u201393","journal-title":"Ann Intern Med"},{"key":"BFncprheum0572_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archinte.159.6.577","volume":"159","author":"CM Weyand","year":"1999","unstructured":"Weyand CM et al. (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159: 577\u2013584","journal-title":"Arch Intern Med"},{"key":"BFncprheum0572_CR14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB and Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805\u20131812","journal-title":"J Clin Invest"},{"key":"BFncprheum0572_CR15","first-page":"396","volume":"86","author":"B M\u00fcller","year":"2001","unstructured":"M\u00fcller B et al. (2001) Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86: 396\u2013404","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncprheum0572_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1086\/426148","volume":"39","author":"B M\u00fcller","year":"2004","unstructured":"M\u00fcller B et al. (2004) Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 39: 1867\u20131868","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0572_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","volume":"341","author":"M Assicot","year":"1993","unstructured":"Assicot M et al. (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341: 515\u2013518","journal-title":"Lancet"},{"key":"BFncprheum0572_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1086\/421997","volume":"39","author":"L Simon","year":"2004","unstructured":"Simon L et al. (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39: 206\u2013217","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0572_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s001340051006","volume":"25","author":"T Nishikura","year":"1999","unstructured":"Nishikura T (1999) Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med 25: 1031","journal-title":"Intensive Care Med"},{"key":"BFncprheum0572_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1086\/368088","volume":"36","author":"E Nylen","year":"2003","unstructured":"Nylen E et al. (2003) The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 36: 823\u2013824","journal-title":"Clin Infect Dis"},{"key":"BFncprheum0572_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/ard.62.4.337","volume":"62","author":"I Del\u00e8vaux","year":"2003","unstructured":"Del\u00e8vaux I et al. (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62: 337\u2013340","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0572_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/adc.2005.077446","volume":"91","author":"R Arkader","year":"2006","unstructured":"Arkader R et al. (2006) Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 91: 117\u2013120","journal-title":"Arch Dis Child"},{"key":"BFncprheum0572_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0035-9203(97)90086-9","volume":"91","author":"D Richard-Lenoble","year":"1997","unstructured":"Richard-Lenoble D et al. (1997) Changes in procalcitonin and interleukin 6 levels among treated African patients with different clinical forms of malaria. Trans R Soc Trop Med Hyg 91: 305\u2013306","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"BFncprheum0572_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF02962246","volume":"26","author":"V Schwenger","year":"1998","unstructured":"Schwenger V et al. (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26: 274\u2013276","journal-title":"Infection"},{"key":"BFncprheum0572_CR25","first-page":"123","volume":"24","author":"CA Scire","year":"2006","unstructured":"Scire CA et al. (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24: 123\u2013128","journal-title":"Clin Exp Rheumatol"},{"key":"BFncprheum0572_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2362.1996.159291.x","volume":"26","author":"E Malle","year":"1996","unstructured":"Malle E and De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26: 427\u2013435","journal-title":"Eur J Clin Invest"},{"key":"BFncprheum0572_CR27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1194\/jlr.M100388-JLR200","volume":"43","author":"SP Tam","year":"2002","unstructured":"Tam SP et al. (2002) Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A. J Lipid Res 43: 1410\u20131420","journal-title":"J Lipid Res"},{"key":"BFncprheum0572_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.0300-9475.2004.01369.x","volume":"59","author":"CF Thorn","year":"2004","unstructured":"Thorn CF et al. (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152\u2013158","journal-title":"Scand J Immunol"},{"key":"BFncprheum0572_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/art.21518","volume":"54","author":"RH Mullan","year":"2006","unstructured":"Mullan RH et al. (2006) Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 54: 105\u2013114","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0572_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/ard.60.2.124","volume":"60","author":"T Yamada","year":"2001","unstructured":"Yamada T et al. (2001) Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 60: 124\u2013127","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0572_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358: 24\u201329","journal-title":"Lancet"},{"key":"BFncprheum0572_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/ard.2005.042143","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P et al. (2006) Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65: 564\u2013572","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0572_CR33","first-page":"322","volume":"28","author":"B Fautrel","year":"2001","unstructured":"Fautrel B et al. (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 28: 322\u2013329","journal-title":"J Rheumatol"},{"key":"BFncprheum0572_CR34","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","volume":"44","author":"Y Kawaguchi","year":"2001","unstructured":"Kawaguchi Y et al. (2001) Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 44: 1716\u20131717","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0572_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cyto.2005.03.002","volume":"31","author":"MA Navarro","year":"2005","unstructured":"Navarro MA et al. (2005) Immune-regulation of the apolipoprotein A-I\/C-III\/A-IV gene cluster in experimental inflammation. Cytokine 31: 52\u201363","journal-title":"Cytokine"},{"key":"BFncprheum0572_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbrc.2005.12.070","volume":"340","author":"JR Nofer","year":"2006","unstructured":"Nofer JR et al. (2006) Low density lipoproteins inhibit the Na+\/H+ antiport in human platelets via activation of p38MAP kinase. Biochem Biophys Res Commun 340: 751\u2013757","journal-title":"Biochem Biophys Res Commun"},{"key":"BFncprheum0572_CR37","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/blood.V97.8.2381","volume":"97","author":"N Hyka","year":"2001","unstructured":"Hyka N et al. (2001) Apolipoprotein A-I inhibits the production of interleukin-1\u03b2 and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97: 2381\u20132389","journal-title":"Blood"},{"key":"BFncprheum0572_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1194\/jlr.R400017-JLR200","volume":"46","author":"A Chait","year":"2005","unstructured":"Chait A et al. (2005) Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46: 389\u2013403","journal-title":"J Lipid Res"},{"key":"BFncprheum0572_CR39","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.jacc.2005.06.080","volume":"46","author":"BJ Ansell","year":"2005","unstructured":"Ansell BJ et al. (2005) High-density lipoprotein function recent advances. J Am Coll Cardiol 46: 1792\u20131798","journal-title":"J Am Coll Cardiol"},{"key":"BFncprheum0572_CR40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/01.CCM.0000114820.47460.0A","volume":"32","author":"C Chenaud","year":"2004","unstructured":"Chenaud C et al. (2004) Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 32: 632\u2013637","journal-title":"Crit Care Med"},{"key":"BFncprheum0572_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2004.08.036","volume":"178","author":"S Marchesi","year":"2005","unstructured":"Marchesi S et al. (2005) Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis 178: 345\u2013350","journal-title":"Atherosclerosis"},{"key":"BFncprheum0572_CR42","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.1780361111","volume":"36","author":"RG Lahita","year":"1993","unstructured":"Lahita RG et al. (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36: 1566\u20131574","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0572_CR43","first-page":"1701","volume":"26","author":"YB Park","year":"1999","unstructured":"Park YB et al. (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26: 1701\u20131704","journal-title":"J Rheumatol"},{"key":"BFncprheum0572_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00281-006-0012-9","volume":"27","author":"B M\u00f6ller","year":"2006","unstructured":"M\u00f6ller B and Villiger P (2006) Inhibition of IL-1, IL-6, and TNF-alpha in immune mediated inflammatory diseases. Spinger Semin Immun 27: 391\u2013408","journal-title":"Spinger Semin Immun"},{"key":"BFncprheum0572_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/art.1780360408","volume":"36","author":"P Roux-Lombard","year":"1993","unstructured":"Roux-Lombard P et al. (1993) Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 36: 485\u2013489","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0572_CR46","first-page":"303","volume":"24","author":"C Gabay","year":"1997","unstructured":"Gabay C et al. (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24: 303\u2013308","journal-title":"J Rheumatol"},{"key":"BFncprheum0572_CR47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00005792-200209000-00002","volume":"81","author":"KM Hull","year":"2002","unstructured":"Hull KM et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81: 349\u2013368","journal-title":"Medicine (Baltimore)"},{"key":"BFncprheum0572_CR48","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/rheumatology\/keh357","volume":"43","author":"E Drewe","year":"2004","unstructured":"Drewe E et al. (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43: 1405\u20131408","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0572_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","volume":"17","author":"S Stojanov","year":"2005","unstructured":"Stojanov S and Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17: 586\u2013599","journal-title":"Curr Opin Rheumatol"},{"key":"BFncprheum0572_CR50","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.139.5.1546","volume":"139","author":"P Seckinger","year":"1987","unstructured":"Seckinger P et al. (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139: 1546\u20131549","journal-title":"J Immunol"},{"key":"BFncprheum0572_CR51","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1084\/jem.20050640","volume":"201","author":"CA Dinarello","year":"2005","unstructured":"Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355\u20131359","journal-title":"J Exp Med"},{"key":"BFncprheum0572_CR52","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/rheumatology\/36.12.1283","volume":"36","author":"G Sturfelt","year":"1997","unstructured":"Sturfelt G et al. (1997) Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 36: 1283\u20131289","journal-title":"Br J Rheumatol"},{"key":"BFncprheum0572_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.CCM.0000150661.69565.D8","volume":"33","author":"C Miki","year":"2005","unstructured":"Miki C et al. (2005) Deficiency in systemic interleukin-1 receptor antagonist production as an operative risk factor in malnourished elderly patients with colorectal carcinoma. Crit Care Med 33: 177\u2013180","journal-title":"Crit Care Med"},{"key":"BFncprheum0572_CR54","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss G and Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011\u20131023","journal-title":"N Engl J Med"},{"key":"BFncprheum0572_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/10408360591001886","volume":"42","author":"L Punzi","year":"2005","unstructured":"Punzi L et al. (2005) New biochemical insights into the pathogenesis of osteoarthritis and the role of laboratory investigations in clinical assessment. Crit Rev Clin Lab Sci 42: 279\u2013309","journal-title":"Crit Rev Clin Lab Sci"},{"key":"BFncprheum0572_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ncprheum0132","volume":"2","author":"P Garnero","year":"2006","unstructured":"Garnero P (2006) Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract Rheumatol 2: 116\u2013117","journal-title":"Nat Clin Pract Rheumatol"},{"key":"BFncprheum0572_CR57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/oso\/9780198566304.003.0021","volume-title":"Rheumatoid Arthritis: New Frontiers in Pathogenesis and Treatment","author":"T Saxne","year":"2006","unstructured":"Saxne T et al. (2006). Biomarkers for cartilage and bone in rheumatoid arthritis. In Rheumatoid Arthritis: New Frontiers in Pathogenesis and Treatment, edn 2 301\u2013313 (eds Firestein GS et al.) Oxford: Oxford University Press"},{"key":"BFncprheum0572_CR58","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/rheumatology\/40.5.544","volume":"40","author":"P Roux-Lombard","year":"2001","unstructured":"Roux-Lombard P et al. (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 40: 544\u2013551","journal-title":"Rheumatology"},{"key":"BFncprheum0572_CR59","doi-asserted-by":"crossref","unstructured":"Van der Pouw Kraan TC et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis [doi: 10.1136\/ard.2006.063412]","DOI":"10.1136\/ard.2006.063412"},{"key":"BFncprheum0572_CR60","first-page":"152","volume-title":"The Cytokine network frontiers in molecular biology","author":"GW Duff","year":"2000","unstructured":"Duff GW (2000) Genetic variations in cytokines and relevance to inflammation and diseases. In The Cytokine network frontiers in molecular biology, (vol 25) 152 (ed Balkwill F) Oxford: Oxford University Press"},{"key":"BFncprheum0572_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/hmg\/ddi469","volume":"15","author":"H Chen","year":"2006","unstructured":"Chen H et al. (2006) Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Human Mol Gen 15: 519\u2013529","journal-title":"Human Mol Gen"},{"key":"BFncprheum0572_CR62","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1002\/pmic.200600017","volume":"6","author":"W Hueber","year":"2006","unstructured":"Hueber W and Robinson WH (2006) Proteomic biomarkers for autoimmune disease. Proteomics 6: 4100\u20134105","journal-title":"Proteomics"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0572","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T17:40:19Z","timestamp":1708191619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["BFncprheum0572"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0572","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}